Dyadic International, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DYAI research report →
Range $3 – $3
Price Chart
About the company
Dyadic International, Inc. operates as a U. S.
- CEO
- Mark A. Emalfarb
- IPO
- 2008
- Employees
- 5
- HQ
- Jupiter, FL, US
Get TickerSpark's AI analysis on DYAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.51M
- P/E
- -1.52
- Fwd P/E
- 1.20
- PEG
- -0.06
- P/S
- 4.17
- P/B
- -4.26
- EV/EBITDA
- -1.78
- Div Yield
- 0.00%
- Gross Margin
- 17.66%
- Op Margin
- -264.93%
- Net Margin
- -254.01%
- ROE
- 676.56%
- ROIC
- -219.00%
Latest fiscal year · YoY change
- Revenue
- $1.23M-64.7%
- Gross Profit
- $-1,087,549-147.3%
- Op Income
- $-7,145,916
- Net Income
- $-7,364,628-26.8%
- EPS
- $-0.23-15.0%
- OCF Growth
- -43.5%
- FCF Growth
- -43.5%
- 52W High
- $1.60
- 52W Low
- $0.28
- 50D MA
- $0.40
- 200D MA
- $0.72
- Beta
- 1.08
- RSI (14)
- 31
- Avg Volume
- 140.81K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Dyadic said Q3 progress was real but early, with first direct product sales, more partner commercialization, and strong biopharma validation, while management emphasized that meaningful recurring revenue will take time.· November 12, 2026
- First direct commercial protein sales were recorded in Q3, mainly recombinant transferrin and DNase 1, but management said the revenue is not yet financially material.
- Partner commercialization expanded: IBT Bioservices launched 6 Dyadic-produced RUO protein products, ProLiant continued building AlbuFree DX, and Enzymes sold its second chymosin product in October.
- The STRiVE collaboration on alpha-lactalbumin was highlighted as a vertically integrated path to market, with an initial 10-ton agreement and up to 100 tons in the following year.
- Biopharma data remained a key validation point, including ~12.1 g/L and 13.2 g/L antibody yields in Gates-funded work and a rapid vaccine antigen workflow reduced to about 15 days.
- Management repeatedly said adoption is slower than expected, largely because customers need time to qualify products in regulated workflows and because Dyadic is still capital constrained.
Total revenue for the third quarter of 2026 was approximately $449,000, down 61% from approximately $1.17 million in Q3 2025. Revenue included approximately $162,000 of research and development revenue, $276,000 of grant revenue, and $10,000 of license fee revenue. Total cost of revenue was approximately $375,000, down 63% year over year. Internal R&D expenses were approximately $430,000, down 25% year over year, and G&A was approximately $1.45 million, down 2% year over year. Loss from operations was approximately $1.8 million versus approximately $1.9 million last year, net loss was approximately $1.4 million or $0.04 per share versus approximately $2 million or $0.06 per share, and nine-month net loss was approximately $5.4 million or $0.15 per share versus $5.8 million or $0.18 per share. Cash, cash equivalents, restricted cash, and investment-grade securities were approximately $6 million at quarter end versus approximately $8.6 million at year-end. Dyadic completed a registered direct offering and concurrent private placements of warrants that generated gross proceeds of $2.9 million. Management expects cash usage to continue at a similar level, varying by quarter, while working to expand commercial revenues and pursue financing alternatives. For Q4, Dyadic expects to recognize a $225,000 contractual payment from Enzymes related to its first commercial sale of camel chymosin produced with DAPIBUS.
Joe Hazelton struck a cautious but constructive tone, saying Dyadic is transitioning from technology development toward a commercial model built around direct sales, distribution, licensing, and partner-led commercialization. He stressed that the company is increasingly focused on larger strategic partnerships and supply arrangements rather than trying to fund every product internally. His comments suggested optimism about platform validation, but also clear realism that conversion from sampling to recurring orders is taking longer than hoped.
Ping Wang Rawson focused on the financial discipline side of the story, noting revenue of approximately $449,000 in Q3 and a net loss of approximately $1.4 million, or $0.04 per share. She highlighted lower grant and collaboration activity as the main driver of the revenue decline, while internal R&D spending fell 25% year over year to approximately $430,000 and cost of revenue declined 63% to approximately $375,000. She also pointed to approximately $6 million in cash, the $2.9 million gross proceeds from the warrant-linked financing, and operating cash usage of approximately $5.3 million for the first nine months, or about $590,000 per month.
Analysts pressed management on why adoption is slower than expected and whether the modest product sales level is a good baseline going forward. Hazelton said the main issue is customer qualification in regulated workflows, especially for cell culture media and therapeutic-adjacent applications, where buyers need proof of performance, quality, and regulatory suitability before switching suppliers. On STRiVE, management said the deal is a supply agreement with an initial 10-ton commitment and up to 100 tons in the following year, and that the company is using the partnership to build a broader customer base rather than relying on a single buyer.
The bullish read is that Dyadic is now showing real commercial proof points across several channels: direct sales, distribution, partner commercialization, and a new integrated supply agreement with STRiVE. The biopharma data also looked strong, with high antibody yields, human-like glycosylation, and faster antigen development timelines, which management believes could support future licensing or strategic deals.
The main bear case is that management admitted direct sales are still modest and customer adoption is slower than expected, especially in more regulated end markets. Dyadic is also still constrained by cash and says it cannot build inventory or scale commercialization aggressively on its own, so growth depends on partners, external funding, and successful qualification of products before larger orders arrive.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.0%
- Shares Outstanding
- 40.09M
- Float Shares
- 30.86M
of shares held by institutions
40 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Empery Asset Management, LP | 3.35M | ▲ 3.35M |
| Vanguard Capital Management LLC | 928.23K | 0 |
| Vanguard Group Inc | 914.96K | 0 |
| Truist Financial Corp | 326.20K | 0 |
| Geode Capital Management, LLC | 270.12K | ▲ 19.21K |
| Cantor Fitzgerald, L. P. | 204.72K | ▲ 204.72K |
| Blackrock, Inc. | 197.75K | 0 |
| Renaissance Technologies LLC | 158.23K | ▲ 79.44K |
| Marathon Capital Management | 157.60K | ▲ 47.60K |
| Vanguard Fiduciary Trust Co | 139.48K | 0 |
| Sage Mountain Advisors LLC | 106.56K | 0 |
| Citadel Advisors LLC | 93.83K | ▲ 19.50K |
Held by 21 ETFs
Biggest fund positions in DYAI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 26 | Francisco Trust under agreement dated February 28, 1996 | sell | 38,016 |
| Jul 23, 26 | Francisco Trust under agreement dated February 28, 1996 | sell | 54,760 |
| Jul 24, 26 | Francisco Trust under agreement dated February 28, 1996 | sell | 2,616 |
| Jun 6, 24 | Francisco Trust under agreement dated February 28, 1996 | sell | 26,340 |
| Dec 20, 24 | Francisco Trust under agreement dated February 28, 1996 | sell | 25,281 |
| Dec 23, 24 | Francisco Trust under agreement dated February 28, 1996 | sell | 41,143 |
| Dec 24, 24 | Francisco Trust under agreement dated February 28, 1996 | sell | 5,100 |
| Dec 30, 24 | Francisco Trust under agreement dated February 28, 1996 | sell | 40,000 |
| Jan 6, 25 | Francisco Trust under agreement dated February 28, 1996 | sell | 20,000 |
| Jan 7, 25 | Francisco Trust under agreement dated February 28, 1996 | sell | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DYAI coverage
Recent articles, reports, and earnings notes.
No research on DYAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DYAI report →Dyadic: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 13
Dyadic International, Inc. (DYAI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
Dyadic Announces Third Quarter 2026 Financial Results and Recent Developments
globenewswire.com · Nov 12
Dyadic's C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations
globenewswire.com · Nov 12
Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.
globenewswire.com · Nov 10
Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026
globenewswire.com · Oct 30
Financial Survey: Lisata Therapeutics (NASDAQ:LSTA) vs. Dyadic International (NASDAQ:DYAI)
defenseworld.net · Oct 15
Dyadic International Targets Commercial Traction as Life Sciences Products Launch
defenseworld.net · Oct 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.